Skip to content

A Case-Control Study Exploring Neural Biomarkers in School-Aged Children with Tic Disorders Based on SERF Magnetoencephalography Technology

A Case-Control Study Exploring Neural Biomarkers in School-Aged Children with Tic Disorders Based on SERF Magnetoencephalography Technology

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600116212
Enrollment
Unknown
Registered
2026-01-06
Start date
2026-01-06
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tic disorder

Interventions

Health Control Group:None

Sponsors

Beijing Childrens Hospital,Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 12 Years

Inclusion criteria

Inclusion criteria: 1. Meets the diagnostic criteria for chronic tic disorder or Tourette syndrome as stipulated in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5); 2. Age 6-12 years old, gender not restricted, right-handed; 3. Able to tolerate MEG examination, without any clear contraindications for MEG examination (such as the presence of non-antimagnetic metal implants in the body), head circumference = 55 cm; 4. Guardians and the subjects (if capable) sign the informed consent form after fully understanding the content.

Exclusion criteria

Exclusion criteria: 1.With severe or unstable physical or mental illnesses, such as cardiac, hepatic, or renal insufficiency; hematological diseases; autoimmune disorders; inherited metabolic diseases; epilepsy; schizophrenia; etc. 2.Comorbid with attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), other neurodevelopmental disorders, as well as affective disorders such as anxiety disorders, depressive disorders, and obsessive-compulsive disorder (OCD). 3.With sensory organ deficits (such as hearing or vision impairment) or cognitive dysfunction, resulting in inability to cooperate with the research tasks. 4.Have taken medications that may significantly affect the central nervous system within 4 weeks prior to enrollment, such as antipsychotics, CNS stimulants, antidepressants, sedative-hypnotics, etc.

Design outcomes

Primary

MeasureTime frame
MEG characteristic indicators (resting-state neural oscillation power spectral density and functional connectivity values; event-related field latency and amplitude; post-stop-signal power changes);

Secondary

MeasureTime frame
Adverse event records;Clinical scale assessments (Yale Global Tic Severity Scale, Premonitory Urge for Tics Scale, etc) and task-based behavioral metrics.;

Countries

China

Contacts

Public ContactWeiZhang;Guojun Zhang

Beijing Childrens Hospital,Capital Medical University

mssxa@163.com+86 10 5961 6361

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026